Micron Stock Plunges 17.7% After Disappointing Q2 Guidance

Micron Technology reported mixed Q1 earnings, exceeding EPS expectations but falling short on revenue. Q2 guidance was significantly below estimates, leading to a sharp 17.7% drop in share price. Analysts lowered price targets, though some maintain a positive outlook. The company anticipates a return to growth in the second half of the fiscal year, driven by AI.

Wall Street Downgrades Send Shockwaves Through Tech and Biotech: C3.ai, Viridian, and More

Wall Street analysts issued several downgrades impacting tech and biotech stocks, including C3.ai, Viridian Therapeutics, NICE Ltd., European Wax Center, and Cabaletta Bio. These actions reflect concerns about growth prospects, valuation, and market uncertainty, prompting investors to reassess their portfolios. The Dow Jones Industrial Average also experienced a significant dip, adding to the overall market volatility.

Market Volatility: Dow Futures Rise Amidst Sharp Stock Drops

U.S. stock futures rose, but several stocks fell sharply in pre-market trading. Lamb Weston’s earnings miss and lowered outlook caused an 18.6% drop in its shares. Micron Technology also underperformed, while other companies like Abacus Life and Lennar experienced significant declines. The market shows volatility, highlighting the need for careful investment strategies.

Nukkleus Inc. (NUKK) Stock Soars 30% on $10M Private Placement for Israeli Defense Tech Acquisition

Nukkleus Inc. (NUKK) shares surged 29.9% premarket after announcing a $10 million private placement to fund the acquisition of Star 26 Capital Inc., which owns 95% of RIMON, an Israeli defense technology firm. RIMON supplies components for the Iron Dome and develops tactical vehicles. The placement will issue 1.66 million units at $6.00 each, closing around December 19th. This acquisition positions Nukkleus for growth in the defense technology sector.

Scroll to Top